NEPH logo

NEPHROS INC

NEPHNASDAQ
πŸ† #4513 by market capUS Equity
$203.39β–² $7.14 (+3.51%)
Simulated price
πŸ””
Track NEPH
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.5%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$44M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+24.2%
Healthy
πŸ“ŠGross Margin
61.3%
High
πŸ’΅FCF Margin
4.9%
Moderate
βš–οΈP/S Ratio
2.1x
Cheap
Otter Score
68
Fair
No chart data available for NEPH.

Trading Snapshot

Day Range
$201.94 – $204.62
52-Week Range
$2.66 – $6.42
Volume
$4.92B
Avg Volume
$5.71B
Shares Outstanding
10.9M
Next Earnings
Nov 21, 2026

Fundamentals Snapshot

Annual Revenue
$19M
Last Q Revenue
$6M
P/E Ratio
25.1
P/S Ratio
2.1x
EPS (TTM)
$0.16
Dividend Yield
β€”
Dilution (1yr)
+3.9%

Why Investors Own NEPH

  • βœ“High-growth profile β€” revenue up -6.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 35% gross margin and 19% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NEPH logo

NEPHROS INC

NEPH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$19Mβ–² +32.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.1%β–Ό βˆ’0.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1Mβ–² +19000.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2Mβ–Ό βˆ’400.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.0Mβ–² +3.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4Mβ–² +$2M YoY
StockOtter Β· stockotter.space

About NEPHROS INC

Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$264.71
β–² +30.1% Upside
High Target$317.72
Low Target$217.44
Based on 29 analysts

Latest News & Updates